On April 28, 2020 Incurix and the National Cancer Center (NCC), reported their entry into an exclusive license agreement for the new c-myc inhibitor program that the NCC and the Korea Research Institute of Chemical Technology (KRICT) jointly developed (Press release, Incurix, APR 28, 2020, View Source;idx=68&page=1&code=news [SID1234643568]). Under the agreement, Incurix will receive the rights to develop, manufacture and exclusively commercialize myc inhibitors in consideration of upfront, potential development/regulatory milestones and royalties on net sales of the license program of Myc inhibitor.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As the transcription factor engaged in the growth and death of cells through interactions with DNAs, the c-myc protein is involved in the occurrence and growth of cancer and is over-expressed in various cancers. Drugs that have already been developed to control c-myc expression have failed in clinical trials because of their low selectivity over target substances and the issues of side effects caused by toxicity. For this reason, there are no c-myc inhibitor drugs that have been commercialized yet. The program that Incurix has in-licensed takes a differentiated approach by having the c-myc protein directly target the DNA interacting site to increase the selectivity against the target and minimize side effects. "We will ensure the success of commercializing the FIC transcription factor-targeting drug, which many global pharmaceutical companies could not yet succeed in," said Dr. Kyung-Chae Jeong, Incurix CEO and Senior Director at the NCC Research Center, who led the study. "If this technology succeeds in the commercialization of a drug that has so far been known as difficult in clinical applications, this will mark a significant milestone to cancer treatment," National Cancer Center Director Lee Eun-sook said. She added, "This licensing agreement is the result of the NCC’s continuous research, and we will continue our efforts for the success in commercialization through a good research cycle of research to commercialization."
Incurix is a case of the NCC’s researcher-led startup and was established in 2018 by the support of bio healthcare company builder New Flight, which leads the commercialization of bio-medical fields.